BE2019C523I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C523I2
BE2019C523I2 BE2019C523C BE2019C523C BE2019C523I2 BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2 BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2
Authority
BE
Belgium
Application number
BE2019C523C
Other languages
Dutch (nl)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C523(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BE2019C523I2 publication Critical patent/BE2019C523I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
BE2019C523C 2004-11-12 2019-05-07 BE2019C523I2 (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (1)

Publication Number Publication Date
BE2019C523I2 true BE2019C523I2 (OSRAM) 2025-02-10

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C523C BE2019C523I2 (OSRAM) 2004-11-12 2019-05-07

Country Status (32)

Country Link
US (4) US7632921B2 (OSRAM)
EP (9) EP1824988B1 (OSRAM)
JP (5) JP2008524117A (OSRAM)
KR (7) KR20120136413A (OSRAM)
CN (6) CN103102406B (OSRAM)
AU (1) AU2005304622B2 (OSRAM)
BE (1) BE2019C523I2 (OSRAM)
BR (2) BR122016022033B8 (OSRAM)
CA (1) CA2586379C (OSRAM)
CY (3) CY1119292T1 (OSRAM)
DK (3) DK2371856T3 (OSRAM)
ES (4) ES2821832T3 (OSRAM)
FR (1) FR19C1031I2 (OSRAM)
HN (1) HN2007015683A (OSRAM)
HR (2) HRP20070268B1 (OSRAM)
HU (5) HUE059193T2 (OSRAM)
IL (3) IL182903A (OSRAM)
LT (5) LT2371856T (OSRAM)
LU (1) LUC00118I2 (OSRAM)
MA (1) MA29663B1 (OSRAM)
MX (3) MX2007005466A (OSRAM)
NL (1) NL300989I2 (OSRAM)
NO (3) NO20210454A1 (OSRAM)
NZ (1) NZ555032A (OSRAM)
PH (2) PH12014500352B1 (OSRAM)
PL (3) PL2363414T3 (OSRAM)
PT (4) PT2363414T (OSRAM)
RU (1) RU2423380C2 (OSRAM)
SI (4) SI1824988T1 (OSRAM)
UA (1) UA95225C2 (OSRAM)
WO (1) WO2006053299A2 (OSRAM)
ZA (1) ZA200703696B (OSRAM)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
HRP20070268B1 (hr) 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
GB2467700A (en) 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
EP2626079A3 (en) * 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
CA2726942A1 (en) 2008-06-04 2009-12-10 Bayer Healthcare Llc Fviii muteins for treatment of von willebrand disease
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
KR20110071012A (ko) * 2008-10-17 2011-06-27 백스터 인터내셔널 인코포레이티드 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
WO2010062768A1 (en) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
EP2368124A4 (en) * 2008-11-24 2012-09-19 Bayer Healthcare Llc METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US8716448B2 (en) * 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
PL2408800T3 (pl) * 2009-03-20 2016-11-30 Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PT3326643T (pt) 2009-12-06 2021-07-12 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de fator viii-fc e métodos para a sua utilização
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
HUE047661T2 (hu) * 2010-02-21 2020-05-28 Bayer Healthcare Llc Eljárás biomolekulák aktiválására és konjugálására
EP3549963B1 (en) 2010-04-15 2022-01-12 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2012006623A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
WO2012166622A1 (en) * 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
EP2666782A1 (en) 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
CN105209487A (zh) * 2013-03-15 2015-12-30 拜耳医药保健有限公司 重组因子viii制剂
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
WO2015059121A1 (en) * 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN106414491B (zh) * 2014-01-20 2021-06-18 奥克塔法马股份有限公司 一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
SG10201808249VA (en) 2014-03-24 2018-10-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
RU2016144057A (ru) 2014-04-10 2018-05-15 Байер Хелскеа Ллк Смешанный состав порошка среды и способ получения жидкой среды для культуры клеток
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
AU2015283822B2 (en) 2014-07-02 2019-10-03 CSL Behring Lengnau AG Modified von willebrand factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
SG11201708754XA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
KR20180098404A (ko) 2016-01-07 2018-09-03 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 폰 빌레브란트 인자
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
EP3476860A4 (en) * 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
JP7252890B2 (ja) 2016-11-11 2023-04-05 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
RU2019118427A (ru) 2016-11-16 2020-12-17 БАЙЕР ХелсКер ЛЛСи Нацеленный на эритроциты фактор viii и способ его применения
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
KR102575788B1 (ko) 2018-05-18 2023-09-08 정저우 젠사이언시스 인코포레이티드 개선된 fviii 융합 단백질 및 이의 용도
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
EP4069269A4 (en) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0730660A4 (en) 1993-10-29 1998-02-25 Incyte Pharma Inc CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
ATE341344T1 (de) * 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
ES2292255T5 (es) 1998-11-10 2017-05-19 Stichting Sanquin Bloedvoorziening Polipéptido del factor 8 con actividad de factor 8:C
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
EP1982732A3 (en) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1373493B1 (en) * 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
PL371278A1 (en) 2002-04-18 2005-06-13 Merck Patent Gmbh Modified factor viii
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
KR101177340B1 (ko) 2003-01-06 2012-08-30 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
DE602004028725D1 (de) 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
HUE043911T2 (hu) 2003-05-23 2019-09-30 Nektar Therapeutics Két PEG láncot tartalmazó PEG származékok
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
HRP20070268B1 (hr) 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
US20080227691A1 (en) 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol

Also Published As

Publication number Publication date
HRP20180481A2 (hr) 2018-06-29
JP6559642B2 (ja) 2019-08-14
FR19C1031I1 (OSRAM) 2019-06-28
EP2363414A2 (en) 2011-09-07
JP2015134780A (ja) 2015-07-27
SI3130601T1 (sl) 2020-11-30
LT2363414T (lt) 2022-10-25
SI1824988T1 (sl) 2017-11-30
CN103102406B (zh) 2015-05-27
KR101468345B1 (ko) 2014-12-03
CY1123384T1 (el) 2021-12-31
HRP20070268A2 (en) 2007-09-30
BR122016022033B1 (pt) 2021-03-02
EP3323829A1 (en) 2018-05-23
NO344606B1 (no) 2020-02-10
LTC1824988I2 (lt) 2021-02-25
CN105148287B (zh) 2019-07-09
SI2371856T1 (sl) 2022-09-30
NO345800B1 (no) 2021-08-09
HUE050542T2 (hu) 2020-12-28
EP1824988A2 (en) 2007-08-29
MX350293B (es) 2017-09-04
BRPI0517795B1 (pt) 2020-03-31
IL232540A (en) 2017-08-31
LUC00118I2 (OSRAM) 2019-12-27
CN105148287A (zh) 2015-12-16
JP6487895B2 (ja) 2019-03-20
HK1182121A1 (en) 2013-11-22
EP3323829B1 (en) 2020-07-15
CY2019024I2 (el) 2019-11-27
EP2363414B1 (en) 2022-05-18
EP3243833B1 (en) 2020-06-17
EP2772500B1 (en) 2019-12-25
US20100081615A1 (en) 2010-04-01
PH12019501613A1 (en) 2020-09-14
NO20072997L (no) 2007-06-27
EP2772500A1 (en) 2014-09-03
JP2017105773A (ja) 2017-06-15
CN103102406A (zh) 2013-05-15
EP3153181A1 (en) 2017-04-12
JP2008524117A (ja) 2008-07-10
US9364520B2 (en) 2016-06-14
CN105753968A (zh) 2016-07-13
EP3130601B1 (en) 2020-07-15
HK1218718A1 (zh) 2017-03-10
HK1117875A1 (en) 2009-01-23
LUC00118I1 (OSRAM) 2019-05-13
PL1824988T3 (pl) 2018-01-31
HUE060016T2 (hu) 2023-01-28
CY2019024I1 (el) 2019-11-27
JP2013067621A (ja) 2013-04-18
EP1824988B1 (en) 2017-04-19
IL234433B (en) 2019-11-28
KR101904630B1 (ko) 2018-10-04
KR101483917B1 (ko) 2015-01-16
HUE033776T2 (en) 2018-01-29
LT1824988T (lt) 2017-10-25
KR20160105928A (ko) 2016-09-07
US9096656B2 (en) 2015-08-04
KR20120136413A (ko) 2012-12-18
DK1824988T3 (en) 2017-08-07
CA2586379A1 (en) 2006-05-18
EP2371856A2 (en) 2011-10-05
PT2363414T (pt) 2022-08-04
CN103214569A (zh) 2013-07-24
ES2930143T3 (es) 2022-12-07
BRPI0517795A8 (pt) 2018-12-26
MX2007005466A (es) 2007-10-19
EP1824988A4 (en) 2008-12-31
CN107082806A (zh) 2017-08-22
ZA200703696B (en) 2008-08-27
WO2006053299A3 (en) 2006-08-24
PT2371856T (pt) 2022-08-12
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
US20130274445A1 (en) 2013-10-17
AU2005304622B2 (en) 2012-03-29
KR20180110192A (ko) 2018-10-08
NZ555032A (en) 2010-02-26
PT1824988T (pt) 2017-07-21
EP3130601A1 (en) 2017-02-15
EP3243834A1 (en) 2017-11-15
JP6109523B2 (ja) 2017-04-05
UA95225C2 (ru) 2011-07-25
US20060115876A1 (en) 2006-06-01
KR20140019489A (ko) 2014-02-14
EP2363414A3 (en) 2012-03-21
WO2006053299A2 (en) 2006-05-18
KR101243564B1 (ko) 2013-03-27
PH12014500352A1 (en) 2015-07-20
CN103214569B (zh) 2016-12-28
CY1119292T1 (el) 2018-02-14
ES2633916T3 (es) 2017-09-26
FR19C1031I2 (fr) 2020-06-05
ES2821832T3 (es) 2021-04-27
JP2017101028A (ja) 2017-06-08
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
MA29663B1 (fr) 2008-08-01
NO20200044A1 (no) 2007-06-27
RU2423380C2 (ru) 2011-07-10
LTPA2019509I1 (lt) 2019-08-26
US20160051633A1 (en) 2016-02-25
PL2363414T3 (pl) 2022-09-05
IL182903A0 (en) 2007-08-19
ES2930159T3 (es) 2022-12-07
AU2005304622A1 (en) 2006-05-18
PH12014500352B1 (en) 2019-09-25
HRP20180481B1 (hr) 2022-02-18
CN101124331B (zh) 2013-04-24
IL182903A (en) 2014-09-30
HRP20070268B1 (hr) 2018-04-20
CN101124331A (zh) 2008-02-13
NL300989I1 (nl) 2019-05-22
HN2007015683A (es) 2011-07-11
LT2371856T (lt) 2022-08-25
BR122016022033B8 (pt) 2021-05-25
EP3243833A1 (en) 2017-11-15
IL232540A0 (en) 2014-06-30
PT3130601T (pt) 2020-10-01
US7632921B2 (en) 2009-12-15
MX392760B (es) 2025-03-24
NL300989I2 (nl) 2019-11-28
KR20130036780A (ko) 2013-04-12
CA2586379C (en) 2012-04-03
KR20140091618A (ko) 2014-07-21
BRPI0517795B8 (pt) 2021-05-25
KR101654011B1 (ko) 2016-09-05
EP2371856A3 (en) 2012-03-14
RU2007121517A (ru) 2008-12-20
EP2371856B1 (en) 2022-05-18
DK2363414T3 (da) 2022-08-08
PL2371856T3 (pl) 2022-08-22
HUE059193T2 (hu) 2022-10-28
BRPI0517795A (pt) 2008-10-21
DK2371856T3 (en) 2022-08-08
LT3130601T (lt) 2020-09-10
HUS1900026I1 (hu) 2022-04-28

Similar Documents

Publication Publication Date Title
BE2024C508I2 (OSRAM)
BE2023C542I2 (OSRAM)
BE2022C549I2 (OSRAM)
BE2021C001I2 (OSRAM)
BE2020C513I2 (OSRAM)
BE2020C517I2 (OSRAM)
BE2019C540I2 (OSRAM)
LUC00118I1 (OSRAM)
BE2019C548I2 (OSRAM)
BE2019C506I2 (OSRAM)
BE2018C045I2 (OSRAM)
BE2020C525I2 (OSRAM)
BE2017C063I2 (OSRAM)
BE2017C027I2 (OSRAM)
BE2017C023I2 (OSRAM)
BE2017C002I2 (OSRAM)
BE2016C067I2 (OSRAM)
BE2014C064I2 (OSRAM)
BE2014C063I2 (OSRAM)
BE2014C010I2 (OSRAM)
BE2013C071I2 (OSRAM)
BE2013C021I2 (OSRAM)
BE2012C025I2 (OSRAM)
JP2005161054A5 (OSRAM)
JP2005178365A5 (OSRAM)